CD19 and diffuse large B-cell lymphoma: As a clinical reference, a study reported patient DLBCL cells to have CD19 expression levels of 5810 CD19/cell, which dropped to 2,021 CD19/cell in relapsed cells following CAR T cell therapy (axicabtagene ciloleucel)31.